How GLP-1 Works

Think of GLP-1 as a volume control for hunger. It turns hunger signals down, makes you feel full faster, and keeps you full for longer. Instead of constant hunger and cravings competing for your attention all day, the signal changes to something closer to "I'm okay, I don't need more food right now."

This also means digestion slows down, blood sugar regulation improves, and appetite drops — which is the same underlying mechanism whether you're taking semaglutide or tirzepatide.

How GLP-1 Helps With Weight Loss

Weight loss is simple in theory: calories in has to be less than calories out. It's hard in practice because hunger fights you, cravings win, and most diets don't hold up under real-life pressure.

GLP-1 changes the terms of that fight. With appetite genuinely reduced, people naturally eat smaller portions, snack less without having to white-knuckle it, and experience fewer cravings. The body starts supporting the goal instead of working against it.

GLP-1 Medications: What's Actually in the Market

This is where things move fast, especially in India.

Semaglutide — the first generation, and now the cheap one

Semaglutide is the molecule behind Ozempic (approved for diabetes), Wegovy (approved for weight loss), and Rybelsus (the oral version). All three come from Novo Nordisk and built the category's global reputation.

Everything changed for Indian buyers on 20 March 2026, when Novo Nordisk's core Indian patent on semaglutide expired. More than 40 Indian manufacturers had generic versions ready to launch, and most moved within the first week. The brand count has already passed 40, though most of that multiplication is the same handful of manufacturers selling the same molecule under two or three different names through different distribution partners — not 40 genuinely different products.

Here's what's actually on the shelf:

Prices are approximate starting costs at the lowest dose and will vary by pharmacy, format, and city.

What this means practically: much cheaper access, far more availability — and genuinely more confusion, because most of these are the identical molecule sold under different names by different sales teams, not different drugs with different strengths.

We asked Dr. Harsha Moole, MD, MBBS, an internal medicine physician who prescribes GLP-1s daily and runs a GLP-1 telehealth practice, what to actually check before choosing a cheaper brand:

On India's fast-growing generic market — the molecule is the same; the risk is quality and handling. Tell patients to check the brand comes from a reputable, regulator-approved manufacturer, that it kept the cold chain (these peptides degrade with heat), and to confirm the actual semaglutide source and dose on the label. Cheapest is not safest when it's something you inject.

— Dr. Harsha Moole, MD, MBBS, internal medicine physician

Tirzepatide — the next generation, and still the premium option

Tirzepatide is the molecule in Mounjaro (Eli Lilly) and Yurpeak — Cipla's co-marketed version of the exact same drug, made by Eli Lilly and distributed through Cipla's wider pharmacy network. Unlike semaglutide, tirzepatide activates two hormone pathways — GLP-1 and GIP — rather than one, which is why it tends to outperform semaglutide on both blood sugar control and weight loss.

There's no generic tirzepatide in India yet, and none is expected imminently. Mounjaro and Yurpeak both run from roughly ₹13,125/month at the 2.5mg starting dose up to ₹25,781/month at 15mg (vial formats cost less per dose than the pen).

In the SURMOUNT-1 trial, average weight loss at 72 weeks was 15.0% at the 5mg dose, 19.5% at 10mg, and 20.9% at 15mg — against 3.1% on placebo. The ~22.5% figure sometimes quoted comes from a narrower analysis counting only people who stayed on treatment for the full trial. For comparison, semaglutide's STEP 1 trial showed an average of 17.3% weight loss over 68 weeks.

Choosing between the two

We asked Dr. Moole what should actually decide semaglutide vs. tirzepatide for someone confused between the two:

The one clinical factor that should decide semaglutide vs tirzepatide is how much weight and A1c reduction a patient actually needs and can tolerate. Tirzepatide hits two receptors — GIP and GLP-1 — and the trials show it delivers stronger A1c drops and bigger average weight loss. If a patient's main goal is weight loss and cost is manageable, I lean tirzepatide. If they want a proven, often more tolerable option, semaglutide is a solid pick. Tolerability and out-of-pocket cost usually tip it for most of my patients.

— Dr. Harsha Moole, MD, MBBS

In practical terms: semaglutide is now the accessible, well-established option. Tirzepatide is stronger on average but still costs roughly six to ten times as much, with no generic on the horizon yet.

Is GLP-1 Safe?

Yes, when used properly and under medical supervision. GLP-1 as a hormone was first identified in 1986 — these aren't new or experimental compounds. They're synthetic versions of a hormone your body already produces, and they've been studied and prescribed for decades before reaching the mainstream weight-loss conversation.

That said, "safe when used properly" is doing real work in that sentence. In India, GLP-1 medications are Schedule H prescription drugs — they require a valid prescription and shouldn't be self-administered based on a friend's recommendation or a social media post.

Who Should Consider GLP-1

GLP-1 or tirzepatide is worth discussing with a doctor if you're carrying significant excess weight, have lost weight before and regained it, or find that hunger and cravings feel genuinely uncontrollable rather than a matter of willpower. For people in that position, GLP-1 offers biological support rather than asking you to out-discipline your own appetite indefinitely.

It's equally important to know who it's not right for. We asked Dr. Moole who shouldn't use GLP-1 even if they qualify by BMI:

GLP-1s are a poor fit for anyone with a personal or family history of medullary thyroid cancer or MEN2 syndrome, severe GI disease like gastroparesis, or a history of pancreatitis. And they're a bad fit for people who can't commit to protein and strength training — because the weight returns hard and fast when the drug stops without a plan.

— Dr. Harsha Moole, MD, MBBS

Dr. Louis Lerebours, MD, a family medicine physician at Freeman Recovery Center, adds pregnancy to that list — GLP-1 medications aren't recommended during pregnancy — alongside the point that BMI alone was never meant to be the only factor. A proper decision requires looking at the whole clinical picture, not just whether someone crosses a number on a chart.

The Honest Part: GLP-1 Works, But It's Not Magic

You still need protein, to protect the muscle you have while losing weight. You still need fiber, for digestion, since appetite dropping sharply can mean eating less of everything, including nutrients your body still needs. And you still need movement — nothing extreme, even walking counts. GLP-1 removes the constant fight with hunger. It doesn't remove the need for basic nutritional consistency.

Removing the Fear

If you feel unsure about starting a GLP-1, that's a completely normal reaction to a genuinely new category of medicine. But it's worth being clear about what it actually is: you're not cheating, and you're not taking a shortcut. You're getting biological support for something your body has been fighting you on. For a lot of people, this is the first time weight loss has felt achievable and sustainable at the same time — not because the medicine does all the work, but because it finally stops working against you.

From Caddy

You don't have to do this perfectly, and you don't have to figure it out alone. GLP-1 works. Tirzepatide works even better, at a real cost difference. And with the right nutrition alongside either one, it works far better than the medication by itself.

If you're on a GLP-1 or thinking about starting one, check your eligibility first, and get Caddy to track the protein, fiber, and overall nutrition that actually determines how well it works for you.

Sources

• Generic Semaglutide Launches in India, including by Dr Reddy's, Zydus, Alkem, Sun Pharma & Glenmark — Lexology, March 2026

• More than 40 generic drug makers set to launch semaglutide in India — Fierce Pharma, March 2026

• Semaglutide Brands in India 2026 — GLP1 Check

• Mounjaro in India (2026): Price, Doses & Side Effects — Sapiens

• Tirzepatide Once Weekly for the Treatment of Obesity — SURMOUNT-1, New England Journal of Medicine, 2022

• Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide — STEP 1 extension, Diabetes Obes Metab, 2022

• Holst, J.J. From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy — Frontiers in Endocrinology, 2019

• Dr. Harsha Moole, MD, MBBS — internal medicine physician, LinkedIn

• Dr. Louis Lerebours, MD — Freeman Recovery Center, staff page